Terms: = Prostate cancer AND SPOP, TEF2, 8405, ENSG00000121067, O43791 AND Prognosis
21 results:
1. Endoplasmic reticulum stress-related genes as prognostic and immunogenic biomarkers in prostate cancer.
Wan L; Fan Y; Wu T; Liu Y; Zhang R; Chen S; Zhao C; Xue Y
Eur J Med Res; 2024 Apr; 29(1):242. PubMed ID: 38643190
[TBL] [Abstract] [Full Text] [Related]
2. Somatic and Germline Variants Affect prognosis and Susceptibility in prostate cancer.
Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
[TBL] [Abstract] [Full Text] [Related]
3. Genetic Profiling of African American Patients With Prostatic Adenocarcinoma Metastatic to the Lymph Nodes: A Pilot Study.
Bidot S; Yin J; Zhou P; Zhang L; Deeb KK; Smith G; Hill CE; Xiu J; Bilen MA; Case KB; Tinsley M; Carthon B; Harik LR
Arch Pathol Lab Med; 2024 Mar; 148(3):310-317. PubMed ID: 37327205
[TBL] [Abstract] [Full Text] [Related]
4. Determination of TMPRSS2-ERG, spop, FOXA1, and IDH1 prostate cancer molecular subtypes in Colombian patients and their possible implications for prognosis.
Montero-Ovalle W; Sanabria-Salas MC; Mesa-López de Mesa J; Varela-Ramírez R; Segura-Moreno YY; Sánchez-Villalobos SA; Nuñez-Lemus M; Serrano ML
Cell Biol Int; 2023 May; 47(5):1017-1030. PubMed ID: 36740223
[TBL] [Abstract] [Full Text] [Related]
5. The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies.
Chen L; Zheng Y; Jiang C; Yang C; Zhang L; Liang C
Front Immunol; 2022; 13():1009634. PubMed ID: 36275733
[TBL] [Abstract] [Full Text] [Related]
6. FLG Gene Mutation Up-regulates the Abnormal Tumor Immune Response and Promotes the Progression of prostate cancer.
Zhang P; An Z; Sun C; Xu Y; Zhang Z
Curr Pharm Biotechnol; 2022; 23(14):1658-1670. PubMed ID: 35422210
[TBL] [Abstract] [Full Text] [Related]
7. Detection of disease-causing mutations in prostate cancer by NGS sequencing.
Mangolini A; Rocca C; Bassi C; Ippolito C; Negrini M; Dell'Atti L; Lanza G; Gafà R; Bianchi N; Pinton P; Aguiari G
Cell Biol Int; 2022 Jul; 46(7):1047-1061. PubMed ID: 35347810
[TBL] [Abstract] [Full Text] [Related]
8. spop promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
Luo Z; Wang J; Zhu Y; Sun X; He C; Cai M; Ma J; Wang Y; Han S
Neoplasia; 2021 Oct; 23(10):1037-1047. PubMed ID: 34509929
[TBL] [Abstract] [Full Text] [Related]
9. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.
Liu D; Augello MA; Grbesa I; Prandi D; Liu Y; Shoag JE; Karnes RJ; Trock BJ; Klein EA; Den RB; Demichelis F; Davicioni E; Sboner A; Barbieri CE
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33998599
[TBL] [Abstract] [Full Text] [Related]
10. TGF-β signaling regulates
Jiao C; Meng T; Zhou C; Wang X; Wang P; Lu M; Tan X; Wei Q; Ge X; Jin J
Aging (Albany NY); 2020 May; 12(9):7747-7760. PubMed ID: 32364525
[TBL] [Abstract] [Full Text] [Related]
11. Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive prostate cancer.
Stopsack KH; Nandakumar S; Wibmer AG; Haywood S; Weg ES; Barnett ES; Kim CJ; Carbone EA; Vasselman SE; Nguyen B; Hullings MA; Scher HI; Morris MJ; Solit DB; Schultz N; Kantoff PW; Abida W
Clin Cancer Res; 2020 Jul; 26(13):3230-3238. PubMed ID: 32220891
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic value of the spop mutant genomic subclass in prostate cancer.
Shoag J; Liu D; Ma X; Oromendia C; Christos P; Ballman K; Angulo C; Cai PY; Gaffney C; Klein E; Karnes J; Den RB; Liu Y; Davicioni E; Barbieri CE
Urol Oncol; 2020 May; 38(5):418-422. PubMed ID: 32192889
[TBL] [Abstract] [Full Text] [Related]
13.
Faisal FA; Murali S; Kaur H; Vidotto T; Guedes LB; Salles DC; Kothari V; Tosoian JJ; Han S; Hovelson DH; Hu K; Spratt DE; Baras AS; Tomlins SA; Schaeffer EM; Lotan TL
Clin Cancer Res; 2020 Jun; 26(11):2595-2602. PubMed ID: 31969336
[TBL] [Abstract] [Full Text] [Related]
14. spop suppresses pancreatic cancer progression by promoting the degradation of NANOG.
Tan P; Xu Y; Du Y; Wu L; Guo B; Huang S; Zhu J; Li B; Lin F; Yao L
Cell Death Dis; 2019 Oct; 10(11):794. PubMed ID: 31624231
[TBL] [Abstract] [Full Text] [Related]
15. Integrative analysis of cancer driver genes in prostate adenocarcinoma.
Zhao X; Lei Y; Li G; Cheng Y; Yang H; Xie L; Long H; Jiang R
Mol Med Rep; 2019 Apr; 19(4):2707-2715. PubMed ID: 30720096
[TBL] [Abstract] [Full Text] [Related]
16. AMPK Promotes spop-Mediated NANOG Degradation to Regulate prostate cancer Cell Stemness.
Wang X; Jin J; Wan F; Zhao L; Chu H; Chen C; Liao G; Liu J; Yu Y; Teng H; Fang L; Jiang C; Pan W; Xie X; Li J; Lu X; Jiang X; Ge X; Ye D; Wang P
Dev Cell; 2019 Feb; 48(3):345-360.e7. PubMed ID: 30595535
[TBL] [Abstract] [Full Text] [Related]
17. Molecular Subtypes of prostate cancer.
Arora K; Barbieri CE
Curr Oncol Rep; 2018 Jun; 20(8):58. PubMed ID: 29858674
[TBL] [Abstract] [Full Text] [Related]
18. Quantification of mutant spop proteins in prostate cancer using mass spectrometry-based targeted proteomics.
Wang H; Barbieri CE; He J; Gao Y; Shi T; Wu C; Schepmoes AA; Fillmore TL; Chae SS; Huang D; Mosquera JM; Qian WJ; Smith RD; Srivastava S; Kagan J; Camp DG; Rodland KD; Rubin MA; Liu T
J Transl Med; 2017 Aug; 15(1):175. PubMed ID: 28810879
[TBL] [Abstract] [Full Text] [Related]
19. Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment.
Yadav SS; Li J; Lavery HJ; Yadav KK; Tewari AK
Urol Oncol; 2015 Jun; 33(6):267.e1-13. PubMed ID: 25791755
[TBL] [Abstract] [Full Text] [Related]
20. Molecular foundations for personalized therapy in prostate cancer.
Fisher KW; Montironi R; Lopez Beltran A; Moch H; Wang L; Scarpelli M; Williamson SR; Koch MO; Cheng L
Curr Drug Targets; 2015; 16(2):103-14. PubMed ID: 25547910
[TBL] [Abstract] [Full Text] [Related]
[Next]